Press Releases

AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome

Investigational gene therapy licensed from The University of Manchester, UK aims to address both physical and CNS manifestations of Hunter syndrome Expands leading pipeline targeting lysosomal disorders with 5 th investigational gene therapy Program expected to enter Phase 1/2 clinical trial in the

Oct 05, 2020

AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 28, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-02, the

Sep 28, 2020

AVROBIO to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming

Sep 25, 2020

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000

Sep 04, 2020

AVROBIO to Present at Three Upcoming Investor Conferences

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming

Sep 03, 2020

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Aug 07, 2020

AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update

New data indicate stable kidney function across the two Fabry disease clinical studies up to 32 months New six-month Phase 2 FAB-201 data from first patient treated using AVROBIO’s plato ® gene therapy platform show continued reduction in toxic metabolite plasma lyso-Gb3 and increased leukocyte and

Aug 06, 2020

AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2020-- AVROBIO, Inc . (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present at the 2020 Wedbush PacGrow

Aug 05, 2020

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Jul 08, 2020

AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials

First patient dosed in AVROBIO’s global Phase 1/2 clinical trial of AVR-RD-02   for Gaucher disease type 1 Second patient dosed in investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 for cystinosis CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 6, 2020-- AVROBIO, Inc.

Jul 06, 2020



Displaying 11 - 20 of 44

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.